Calif. Bill to Decriminalize Psychedelics Scrapped After Key Provisions Gutted
By reMind Staff — Legislative efforts to decriminalize psychedelics in California were stymied Friday after opponents gutted key provisions from the bill, reducing its scope to merely an official study of the proposal. State Bill 519 would have decriminalized for people over 21 the possession and personal use of certain psychedelics — including LSD, mushrooms, […]
Mydecine Announces Resignation of Board Directors
By reMind Staff — A group of directors resigned from Mydecine Innovations Group on Friday, sparking a major transition at the Denver-based biotech. Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale resigned as directors, according to a company press release. “The departures are part of a larger organizational shift that will allow […]
Sacred Garden’s NFT Offers Novel Way to Connect with Psychedelic Plants
By Brad Dunn — As public interest in psychedelics races far ahead of public access to psychedelics, a new blockchain-based program is bridging the gap between entheogenic plants and those who want to experience them personally — and legally. Last week, Sacred Garden, a “real and virtual psychedelic plant community,” began selling non-fungible tokens (NFTs) […]
Genetics Affects Therapeutic Impact of Psychedelics, New Study Finds
By Brad Dunn — Researchers at the University of North Carolina have found that genetic variations in brain chemistry explains why some people don’t respond as beneficially to psychedelic therapy as others. A new study from UNC’s School of Medicine, published in ACS Chemical Neuroscience, discovered that common variants in the serotonin receptor 5-HT2A explain […]
Oregon to Finalize Rules on Legalized Psilocybin Services by December
By reMind Staff — Oregon lawmakers have set a deadline of Dec. 31, 2022, to establish formal rules on the production and administration of psilocybin — just three days before it begins accepting license applications from service providers. Measure 109, aka the Oregon Psilocybin Services Act, legalized the psychedelic beginning in 2023, allowing individuals age […]
Aaron Rodgers: Ayahuasca Helped Fuel Back-to-Back MVP Seasons
By reMind Staff — Green Bay Packers star Aaron Rodgers credits the “two best seasons” of his NFL career to an ayahuasca experience he had in South America. Appearing on the Aubrey Marcus Podcast Wednesday, the legendary quarterback revealed that his consumption of the psychedelic — a plant-based concoction containing DMT — helped him shift […]
TheraPsil CEO: ‘Landmark Case’ Will Legalize Psychedelics in Canada
By Brad Dunn — Canadian nonprofit TheraPsil is leading a new patient-based lawsuit against the federal government to expand access to psilocybin and related therapies — a case it believes will open the door to national legalization of psychedelics. Last week, seven patients and one healthcare practitioner filed a charter challenge claiming the country’s stringent […]
End-of-Life Psilocybin Retreat Opens in Jamaica, Plus New Training Program for Death Doulas
By reMind Staff — The Diaspora Psychedelic Society has launched two new programs in Jamaica aimed at easing the anxiety and depression associated with life-threatening illnesses and the dying process: Sacred Transitions End-of-Life Retreats and Psychedelic End-of-Life Doula Training. The Sacred Transitions End-of-Life Retreat offers psilocybin explorations with facilitated discussions on the topics of death […]
Morgan Stanley: Psychedelics Could Pose ‘Fundamental Change’ to Mental Health
By reMind Staff — Investment firm Morgan Stanley has released an upbeat analysis of the emerging marketplace for psychedelic medicines and therapies. The report, written by the firm’s Counterpoint Global team of analysts, says the impact of breakthrough psychedelic drugs could far exceed current expectations: “Beyond mental illness and pain-related diseases, psychedelics have the potential […]
Biden Administration Prepping for Legalized MDMA, Psilocybin
By Brad Dunn — Officials have urged the Biden administration to prepare for the likelihood that the FDA will approve MDMA and psilocybin for breakthrough therapies within the next two years. In correspondence made public between the U.S. Dept of Health and Human Services and Rep. Madeleine Dean (D-Pa.), the administration indicated it is “exploring […]
